IPM Take
Psychedelic psychiatry is becoming harder to dismiss as an interesting experiment on the margins of medicine. Definium now has two positive Phase III studies in generalized anxiety disorder for DT120 ODT. Panorama reported durable benefit through week 12 after a single supervised administration, pushing the discussion beyond whether lysergide can produce a signal and toward whether psychiatric systems could actually deliver it.
The drug may be given once. The treatment is not one event. Supervision, patient selection, several hours of clinical capacity and follow-up become part of the therapeutic model, which means access inequality can be built into the intervention before approval even arrives.
Executive Summary
Definium Therapeutics reported positive topline results from Panorama, its second Phase III trial of DT120 ODT, lysergide, in adults with generalized anxiety disorder.
The study enrolled 245 participants. At week 12, participants receiving a single 100 µg dose had an LS mean HAM-A reduction of 9.8 points, compared with 4.7 points with placebo, producing a placebo-adjusted difference of 5.1 points, p<0.0001, with Cohen’s d=0.64. The trial also met its key secondary efficacy endpoints.
Most adverse events were reported as mild to moderate and concentrated on the dosing day. The most common included illusion, nausea and headache. Definium reports no drug-related serious adverse events and plans a pre-NDA meeting in the fourth quarter of 2026.
These are company-reported topline findings, not yet a peer-reviewed Phase III publication.
Why it matters
- Patients / advocates: A single-administration treatment model could be important for people who remain symptomatic despite conventional long-term treatment.
- Clinicians: The treatment model requires careful selection, preparation, monitoring and follow-up rather than conventional prescribing alone.
- Hospitals / providers: Several hours of supervised administration create staffing and physical-capacity requirements.
- Payers: Reimbursement will have to account for the treatment infrastructure, not price the intervention as if it were simply a tablet.
Generalized anxiety disorder is frequently described with language that makes it sound ordinary. Chronic anxiety is not ordinary worry. It can occupy sleep, work, relationships, decision-making and the basic sense that daily life is safe enough to move through without constant internal alarm.
Panorama matters because it is a second successful Phase III GAD study rather than an isolated psychedelic experiment. A single supervised dose produced a statistically significant treatment difference at week 12, while improvement was reported from early time points onward.
The difficult part begins if the regulatory programme succeeds. Lysergide administration in these trials involves monitored clinical sessions lasting hours. The intervention therefore requires staff, space, safety procedures and follow-up in a mental-health system that already struggles to provide basic appointments.
That creates an immediate equity problem. Wealthy urban centres and private interventional-psychiatry services can adapt faster than overstretched public systems. A treatment capable of producing rapid benefit could therefore reach the best-connected patients first.
The next psychedelic debate should not be whether the therapy looks unconventional. It should be whether the evidence is robust and whether the care model can be made accessible without turning a new psychiatric treatment into a premium service.
